Phase 2 Safety and Efficacy Study of a Vitamin D Compound (DP001) in Postmenopausal Women With Low Bone Mineral Density
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the effect of a 1-year administration of the vitamin D analog
2-methylene-19-nor-(20S)-1alpha, 25-dihydroxyvitamin D3 (DP001) on bone mineral density
(BMD), safety, and tolerability.
Phase:
Phase 2
Details
Lead Sponsor:
Deltanoid Pharmaceuticals
Treatments:
Bone Density Conservation Agents Dihydroxycholecalciferols Ergocalciferols Retinol palmitate Vitamin A Vitamin D Vitamins